Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/5/2024 | $134.00 | Outperform | Oppenheimer |
| 6/24/2024 | $145.00 | Buy | Needham |
| 6/18/2024 | $155.00 | Buy | Guggenheim |
| 5/1/2024 | $117.00 | Outperform | Robert W. Baird |
| 9/19/2023 | $10.00 | Buy | Truist |
| 6/6/2022 | $4.00 | Outperform → Neutral | Wedbush |
| 12/16/2021 | $48.00 | Buy | HC Wainwright & Co. |
| 8/26/2021 | $28.00 | Buy | B of A Securities |
BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming investor conferences in November 2024. Praxis management will participate in a fireside chat at the Truist Securities BioPharma Symposium, taking place in the Lotte New York Palace Hotel in New York, NY on November 7, 2024 at 9:40am ET.Praxis management will also be participating in a fireside chat at the Guggenheim Securitie
Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registrational Cohort 2 of EMBOLD study recruiting following unprecedented seizure freedom seen in positive topline EMBOLD results for Cohort 1 in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) Vormatrigine (PRAX-628) on track for topline from POWER1 study in focal epilepsy and RADIANT study in focal and generalized epilepsy in 2025 Maintains runway into 2027 BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic i
BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the third quarter ended September 30, 2024, before the financial markets open on Wednesday, November 6, 2024. The Company will host a live webcast the same morning at 8am ET, which can be accessed by visiting this registration link. This live webcast will also be available through the Events & Presentations page of the Investors + Media se
4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
Oppenheimer initiated coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $134.00
Needham initiated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $145.00
Guggenheim initiated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $155.00
PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide therapeutic window Cash and investments of $165.4 million as of June 30, 2022 supports runway into 1Q24 BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the second quarter of 2022
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the appointment of Jill DeSimone to its board of directors. "We are very excited to have Jill join the Praxis board of directors. She is an ideal fit for the Praxis board with her impressive background as a global business leader for multi-billion-dollar products, unique insights into product strategy and portfolio prioritization, and breadth of experience advocating for excellence
BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced the appointment of Megan Sniecinski as chief business officer and provided key updates on members of the executive leadership team. Praxis has promoted Alyssa Wyant to chief regulatory and quality officer and Karl Hansen, Ph.D., to chief technical operations officer. In addition, chief scientific officer and co-founder, Steven Petrou, Ph.D., has decided to fully dedicate his time to Praxis upon stepping
SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
10-Q - Praxis Precision Medicines, Inc. (0001689548) (Filer)
8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
8-K - Praxis Precision Medicines, Inc. (0001689548) (Filer)
4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Shares of NVIDIA Corporation (NASDAQ:NVDA) rose during Tuesday's session. Keybanc analyst John Vinh maintained NVIDIA with an Overweight and raised the price target from $130 to $180. NVIDIA shares gained 3.5% to $132.65 on Tuesday. Here are some other big stocks recording gains in today’s session. Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares rose 21.7% to $38.91. Jumia Technologies AG (NYSE:JMIA) shares surged 20.7% to $10.22 after Benchmark initiated coverage on the stock with a Buy rating and $14 price target. Arlo Technologies, Inc. (NYSE:ARLO) shares gained 14.5% to $15.80 afte
Piper Sandler analyst Yasmeen Rahimi maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Overweight and maintains $270 price target.
Needham initiated coverage on Praxis Precision Medicines Inc (NASDAQ:PRAX), a clinical-stage biopharmaceutical company, engaged in the development of therapies for central nervous system disorders. The company’s lead product ulixacaltamide for essential tremor (ET) is undergoing Essential3 Phase 3 program, with topline results expected in the second half of 2024 to support a planned New Drug Application (NDA) submission in 2025. The analyst writes that sales of Ulixa for essential tremor (ET), if successful in Phase 3, could peak at over $1 billion in 2030 (60% probability of success). Needham writes, “value of ulixacaltamide in essential tremor alone is underappreciated at current
Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; NDA filing anticipated in 2025 Registrational Cohort 2 of EMBOLD study recruiting following unprecedented seizure freedom seen in positive topline EMBOLD results for Cohort 1 in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) Vormatrigine (PRAX-628) on track for topline from POWER1 study in focal epilepsy and RADIANT study in focal and generalized epilepsy in 2025 Maintains runway into 2027 BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic i
BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report its financial results from the third quarter ended September 30, 2024, before the financial markets open on Wednesday, November 6, 2024. The Company will host a live webcast the same morning at 8am ET, which can be accessed by visiting this registration link. This live webcast will also be available through the Events & Presentations page of the Investors + Media se
BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will share the topline results from the Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs) on Tuesday, September 3, 2024, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:00 a.m. ET to discuss the trial results. Conference Call a